局部枸橼酸钠联合小剂量肝素钠抗凝在脓毒症并急性肾损伤患者CRRT中的应用价值

doi:10.3760/cma.j.cn441417-20240828-09021

摘要/Abstract

摘要：

目的　探究局部枸橼酸钠联合小剂量肝素钠抗凝在脓毒症并急性肾损伤患者连续性血液净化治疗（CRRT）中的应用价值。方法　本研究为随机对照试验。选取2021年1月至2024年1月单县中心医院收治的71例脓毒症并急性肾损伤患者作为研究对象。采用随机数字表法将患者分为对照组（35例）与治疗组（36例）。对照组男18例，女17例；年龄（53.40±12.03）岁。治疗组男18例，女18例；年龄（57.97±10.66）岁。对照组采用局部枸橼酸钠抗凝下CRRT，治疗组采用局部枸橼酸钠联合小剂量肝素钠抗凝下CRRT。比较两组治疗前和治疗后12 h、24 h、48 h跨膜压（TMP）、压力降（PFU）及血小板计数（PLT）；治疗后24 h滤器及静脉壶凝血分级；出血情况（皮肤黏膜、消化道、泌尿道等）。采用独立样本t检验、配对t检验、χ2检验、Fisher确切概率法和秩和检验进行统计学分析。结果　治疗后12 h、24 h、48 h，治疗组TMP均低于对照组［（114.97±22.65）mmHg（1 mmHg=0.133 kPa）比（126.91±22.88）mmHg、（133.28±20.04）mmHg比（143.17±20.30）mmHg、（151.14±17.43）mmHg比（159.80±17.68）mmHg］（均P<0.05）；PFU均低于对照组［（97.58±15.22）mmHg比（105.71±15.85）mmHg、（118.81±13.72）mmHg比（126.51±13.25）mmHg、（140.39±14.19）mmHg比（147.43±12.02）mmHg］（均P<0.05）；两组PLT比较，差异均无统计学意义（均P>0.05）。治疗后24 h，治疗组滤器及静脉壶凝血分级优于对照组（P<0.05）。两组出血总发生率比较，差异无统计学意义（P>0.05）。结论　局部枸橼酸钠联合小剂量肝素钠抗凝下CRRT治疗可延长滤器使用寿命，改善滤器清除炎症介质的效率，治疗效果较好，且未增加治疗风险。

关键词: 枸橼酸钠, , , 抗凝, , , 脓毒症, , , 急性肾损伤, , , 血液净化

Abstract:

Objective　To explore the application value of topical sodium citrate combined with low-dose heparin sodium anticoagulation in the treatment of continuous blood purification (CRRT) in patients with sepsis and acute kidney injury. Methods　This research is a randomized controlled trial. Seventy-one patients with sepsis and acute kidney injury (AKI) who were admitted to Shangxian Central Hospital from January 2021 to January 2024 were selected as the research subjects. The patients were divided into the control group (35 cases) and the treatment group (36 cases) by using the random number table method. There were 18 males and 17 females in the control group, aged (53.40±12.03) years. There were 18 males and 18 females in the treatment group, aged (57.97±10.66) years. The control group was treated with CRRT under topical sodium citrate, and the treatment group was treated with CRRT under topical sodium citrate combined with low-dose heparin sodium anticoagulation. Compare the transmembrane pressure (TMP), pressure drop (PFU) and platelet count (PLT) of the two groups before and after treatment at 12 h, 24 h and 48 h; the coagulation grade of the filter and venous reservoir at 24 h after treatment; and the bleeding conditions (skin and mucous membranes, digestive tract, urinary tract, etc.). Independent sample t test, paired t test, χ² test, fisher exact probability and rank sum test were used for statistical analysis. Results　At 12 h, 24 h and 48 h after treatment, the TMP of the treatment group were lower than those of the control group [(114.97±22.65) mmHg (1 mmHg=0.133 kPa) vs. (126.91±22.88) mmHg, (133.28±20.04) mmHg vs. (143.17±20.30) mmHg, (151.14±17.43) mmHg vs. (159.80±17.68) mmHg] (all P<0.05); and the PFU were lower than those of the control group [(97.58±15.22) mmHg vs. (105.71±15.85) mmHg, (118.81±13.72) mmHg vs. (126.51±13.25) mmHg, (140.39±14.19) mmHg vs. (147.43±12.02) mmHg] (all P<0.05); there were no statistically significant difference in the PLT between the two groups (all P>0.05). At 24 hours after treatment, the coagulation grades of the filters and venous reservoirs of the treatment group were better than those of the control group (P<0.05).There was no statistically significant difference in the total incidence of bleeding between the two groups (P>0.05). Conclusion　The treatment of CRRT under topical sodium citrate combined with low-dose heparin sodium anticoagulation can extend the service life of the filter, improve the efficiency of the filter in removing inflammatory mediators, and the therapeutic effect is good without increasing the treatment risk.

Key words: Sodium citrate, , Anticoagulation, , Sepsis, 　Acute kidney injury, , Blood purification

张珂刘景刚吴瑞荣冯慧.

局部枸橼酸钠联合小剂量肝素钠抗凝在脓毒症并急性肾损伤患者CRRT中的应用价值 [J]. 国际医药卫生导报, 2025, 31(9): 1516-1520.

Zhang Ke, Liu Jinggang, Wu Ruirong, Feng Hui.

The application value of topical sodium citrate combined with low-dose heparin sodium anticoagulation in CRRT for patients with sepsis and acute kidney injury [J]. International Medicine and Health Guidance News, 2025, 31(9): 1516-1520.

参考文献

[1]Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47(11):1181-1247. DOI: 10.1007/s00134-021-06506-y.

[2]潘鑫,谢攀,卓燕,等.枸橼酸钠抗凝在不同血液净化模式中的应用[J].中国血液净化,2020,19(8):543-546.DOI:10.3969/j.issn.1671-4091.2020.08.010.

[3]Lin T, Song L, Huang R, et al. Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies[J]. BMC Nephrol, 2019, 20(1):472. DOI: 10.1186/s12882-019-1661-y.

[4]Ma Y, Chen F, Xu Y, et al. Safety and efficacy of regional citrate anticoagulation during plasma adsorption plus plasma exchange therapy for patients with acute-on-chronic liver failure: a pilot study[J]. Blood Purif, 2019,48(3):223-232. DOI: 10.1159/000500408.

[5]周莉,米绪华,唐万欣,等.低分子肝素抗凝、枸橼酸抗凝和无抗凝剂技术在危重病患者实施连续性静脉-静脉血液滤过中的应用[J].中国血液净化,2007,6(10):566-567.DOI:10.3969/j.issn.1671-4091.2007.10.013.

[6]Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4):c179-c184. DOI: 10.1159/000339789.

[7]董小伟,张文贤,刘伯英,等.不同抗凝方案对急性肾损伤患者连续性肾脏替代治疗中的应用研究[J].中国临床医生杂志,2018,46(9):1040-1042.DOI:10.3969/j.issn.2095-8552. 2018.09.011.

[8]Sethi SK, Sinha R, Jha P, et al. Feasibility of sustained low efficiency dialysis in critically sick pediatric patients: a multicentric retrospective study[J]. Hemodial Int, 2018, 22(2):228-234. DOI: 10.1111/hdi.12605.

[9]李依桥,胡芳.局部枸橼酸钠与普通肝素在连续性肾脏替代疗法中抗凝疗效的Meta分析[J].中外医疗,2020,39(20):34-37,52.DOI:10.16662/j.cnki.1674-0742.2020.20.034.

[10]王晓蕾,姚明慧,曹燕秋,等.局部枸橼酸与普通肝素抗凝用于重症患者血液净化的价值比较[J].中国药业,2019,28(13):73-75.DOI:10.3969/j.issn.1006-4931. 2019.13.023.

[11]王兴梅,叶剑鸿.连续性血液净化中枸橼酸抗凝在急性心力衰竭中的应用评价[J].国际医药卫生导报,2017,23(19):3061-3065.DOI:10.3760/cma.j.issn.1007-1245. 2017.19.031.

[12]温艺超,张振辉,陈伟燕.连续性肾脏替代治疗行枸橼酸体外抗凝补碱策略对比研究[J].国际医药卫生导报,2016,22(12):1708-1710.DOI:10.3760/cma.j.issn.1007-1245. 2016.12.014.

[13]Califano AM, Bitker L, Baldwin I, et al. Circuit survival during continuous venovenous hemodialysis versus continuous venovenous hemofiltration[J]. Blood Purif, 2020, 49(3):281-288. DOI: 10.1159/000504037.

[14]Dunn WJ, Sriram S. Filter lifespan in critically ill adults receiving continuous renal replacement therapy: the effect of patient and treatment-related variables[J]. Crit Care Resusc, 2014, 16(3):225-231.

[15]李佩芸,林丽,张凌,等.连续性肾脏替代治疗体外循环寿命的影响因素分析[J].中国血液净化,2020,19(9):610-613.DOI:10.3969/j.issn.1671-4091.2020.09.009.

[16]国家慢性肾病临床医学研究中心,中国医师协会肾脏内科医师分会,中国急性肾损伤临床实践指南专家组.中国急性肾损伤临床实践指南[J].中华医学杂志,2023,103(42):3332-3366.DOI:10.3760/cma.j.cn112137-20230802- 00133.

[17]中国医师协会肾脏内科医师分会血液透析滤过质控指南工作组.血液透析滤过质量控制临床实践指南[J].中华医学杂志,2024,104(8):571-593.DOI:10.3760/cma.j.cn112137- 20231212-01361.